SCHEMBL5849202

SCHEMBL5849202

CCC(=O)Nc1c(O)ncnc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 3/20 0.42
TSHR P16473 2/20 0.42
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 4/20 0.41
EGFR P00533 1/20 0.38
ADORA2A P29274 2/20 0.38
ATM Q13315 2/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ADORA3 P0DMS8 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
CCR6 P51684 1/20 0.37
MCL1 Q07820 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26789536 0.80 LMNA (0.53) LMNAL3MBTL1GAATSHRCYP1A2
SCHEMBL18773443 0.78 MAP4K4 (0.47) LMNAL3MBTL1GAATSHRCYP1A2
SCHEMBL26789791 0.77 POLB (0.47) LMNAL3MBTL1GAATSHRCYP1A2
SCHEMBL15564197 0.77 L3MBTL1 (0.54) LMNAL3MBTL1GAATSHRCYP1A2
SCHEMBL19151017 0.74 PKM (0.39) GAACYP1A2ALDH1A1MAPTTP53
SCHEMBL17451125 0.73 ADORA3 (0.49) LMNAGAATSHRCYP1A2ALDH1A1
SCHEMBL26792358 0.72 LMNA (0.45) LMNAL3MBTL1GAATSHRCYP1A2
SCHEMBL654805 0.71 GAA (0.58) LMNAGAAALDH1A1EGFRKMT2A
SCHEMBL9948617 0.69 LMNA (0.46) LMNAGAAALDH1A1ADORA2AATM
SCHEMBL10732738 0.69 RAB9A (0.50) LMNAL3MBTL1GAATSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115741-B2 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds ALEXION PHARMACEUTICALS, INC. 2006-10-03 US disclosed
US-20030153556-A1 Piperazine and homopiperazine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-08-14 US disclosed
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153556-A1 Piperazine and homopiperazine compounds HAMP, MPL, F2 LMNA 4352/4885L3MBTL1 4004/4885GAA 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.